Sonoma Pharmaceuticals Logo

Press Releases

Investors
  • Overview
  • Business Development
  • News / Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Presentations
    • Management Team
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Balance Sheet
    • Income Statement
    • Cash Flow
    • Financial Results
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Investor Tools
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed
  • News / Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts

Oculus Innovative Sciences Launches Microcyn(R) Dermatology HydroGel for Relief of Pain and Itch into U.S. Dermatology Healthcare Market

Mar 25, 2010

Oculus Innovative Sciences to Present at the Roth Capital Partners 22nd Annual OC Growth Stock Conference

Mar 11, 2010

Oculus Innovative Sciences Receives First FDA Clearance for Microcyn(R)-Based HydroGel for Dermatology Market with Claims Including Reduction of Itch and Pain Relief

Mar 10, 2010

Oculus Innovative Sciences Reports Third Quarter FY 2010 Financial Results: 30% Reduction in Operating Expenses and 36% Increase in Product Revenue

Feb 4, 2010

Oculus Innovative Sciences Introduces Microcyn(R) Solution for Use in Post-Surgical Wounds to U.S. Hospitals and Physicians

Jan 28, 2010

Oculus Innovative Sciences Announces Fiscal Third Quarter 2010 Financial Results and Corporate Update Release and Conference Call

Jan 26, 2010

Oculus Innovative Sciences to Present at OneMed Forum 2010 During JP Morgan Week in San Francisco

Jan 7, 2010

Oculus Innovative Sciences Provides 2010 U.S. Milestones Update

Dec 3, 2009

Oculus Innovative Sciences' Development Partner, Bayer Animal Health, Receives Regulatory Approvals to Market Microcyn(R)-Based Vetericyn(TM) Animal Healthcare Products in China and Taiwan

Nov 13, 2009

Oculus Innovative Sciences Reports Second Quarter FY 2010: 60% Reduction in Operating Expenses and 16% Increase in Product Revenue (37% in Local Currency)

Nov 5, 2009
RSS
    • 1...
    • 27
    • 28
    • 29
    • 30
    • 31
    • 32
    • 33
    • 34
    • 35
    • 36
    • ...43
    Next